Vol 6, No 3 (2020)
Review paper
Published online: 2020-09-09

open access

Page views 796
Article views/downloads 324
Get Citation

Connect on Social Media

Connect on Social Media

Sekukinumab w leczeniu spondyloartropatii zapalnych

Dorota Sikorska1, Włodzimierz Samborski1
Forum Reumatol 2020;6(3):125-130.

Abstract

W początkowym okresie badań nad patogenezą spondyloartropatii seronegatywnych (SpA) kluczową rolę przypisywano limfocytom Th1 oraz czynnikowi martwicy nowotworów-alfa (TNF-α, tumor necrosis factor alpha). Kolejne lata przyniosły jednak dowody na istotne znaczenie odmiennych czynników zapalnych między innymi interleukiny-17 (IL-17). Sekukinumab, który jest w pełni ludzkim przeciwciałem monoklonalnym neutralizującym prozapalną interleukinę-17A, jest pierwszym i obecnie jedynym zarejestrowanym lekiem biologiczny o innym niż  inhibicja TNF-α mechanizmie działania, którego skuteczność w leczeniu SpA została potwierdzona w badaniach klinicznych. W niniejszej publikacji przedstawimy informacje na temat zastosowania sekukinumabu w leczeniu SpA, wraz z własnymi doświadczeniami klinicznymi.

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009; 68(6): 777–783.
  2. Sieper J, Poddubnyy D. New evidence on the management of spondyloarthritis. Nat Rev Rheumatol. 2016; 12(5): 282–295.
  3. Burton PR, Clayton DG, Cardon LR, et al. Wellcome Trust Case Control Consortium, Australo-Anglo-American Spondylitis Consortium (TASC), Biologics in RA Genetics and Genomics Study Syndicate (BRAGGS) Steering Committee, Breast Cancer Susceptibility Collaboration (UK). Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet. 2007; 39(11): 1329–1337.
  4. DeLay ML, Turner MJ, Klenk EI, et al. HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum. 2009; 60(9): 2633–2643.
  5. Glatigny S, Fert I, Blaton MA, et al. Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats. Arthritis Rheum. 2012; 64(1): 110–120.
  6. Abe Y, Ohtsuji M, Ohtsuji N, et al. Ankylosing enthesitis associated with up-regulated IFN-gamma and IL-17 production in (BXSB x NZB) F(1) male mice: a new mouse model. Mod Rheumatol. 2009; 19(3): 316–322.
  7. Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012; 18(7): 1069–1076.
  8. McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 Family of Cytokines in Health and Disease. Immunity. 2019; 50(4): 892–906.
  9. McGonagle DG, McInnes IB, Kirkham BW, et al. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann Rheum Dis. 2019; 78(9): 1167–1178.
  10. Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol. 2015; 27(2): 127–133.
  11. Maldonado-Ficco H, Perez-Alamino R, Maldonado-Cocco JA. Secukinumab: a promising therapeutic option in spondyloarthritis. Clin Rheumatol. 2016; 35(9): 2151–2161.
  12. van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017; 76(6): 978–991.
  13. Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2019; 71(10): 1285–1299.
  14. Stajszczyk M, Kucharz E, Batko B, et al. Sekukinumab w leczeniu pacjentów z osiową spondyloatropatią — stanowisko ekspertów Polskiego Towarzystwa Reumatologicznego. Forum Reumatologiczne. 2017; 3(2): 110–118.
  15. Langley RG, Elewski BE, Lebwohl M, et al. ERASURE Study Group, FIXTURE Study Group. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014; 371(4): 326–338.
  16. Blauvelt A, Prinz JC, Gottlieb AB, et al. FEATURE Study Group. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015; 172(2): 484–493.
  17. Gottlieb AB, Langley RG, Philipp S, et al. Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials. J Drugs Dermatol. 2015; 14(8): 821–833.
  18. Paul C, Lacour JP, Tedremets L, et al. JUNCTURE study group. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015; 29(6): 1082–1090.
  19. Blauvelt A, Reich K, Warren RB, et al. Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis. Br J Dermatol. 2017; 177(3): 879–881.
  20. Reich K, Sullivan J, Arenberger P, et al. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol. 2019; 181(5): 954–966.
  21. Gottlieb AB, Kubanov A, van Doorn M, et al. Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2·5-year results from GESTURE, a randomized, double-blind, placebo-controlled trial. Br J Dermatol. 2020; 182(4): 889–899.
  22. McInnes IB, Mease PJ, Kirkham B, et al. FUTURE 2 Study Group. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; 386(9999): 1137–1146.
  23. Mease P, van der Heijde D, Landewé R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018; 77(6): 890–897.
  24. Mease PJ, Kavanaugh A, Reimold A, et al. Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. RMD Open. 2018; 4(2): e000723.
  25. Mease PJ, Kavanaugh A, Reimold A, et al. FUTURE 1 study group. Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study. ACR Open Rheumatol. 2020; 2(1): 18–25.
  26. van der Heijde D, Mease PJ, Landewé RBM, et al. Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. Rheumatology (Oxford). 2020; 59(6): 1325–1334.
  27. Marzo-Ortega H, Sieper J, Kivitz A, et al. Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2. RMD Open. 2017; 3(2): e000592.
  28. Baraliakos X, Braun J, Deodhar A, et al. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open. 2019; 5(2): e001005.
  29. Pavelka K, Kivitz AJ, Dokoupilova E, et al. MEASURE 3 study group. Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study. ACR Open Rheumatol. 2020; 2(2): 119–127.